Multidrug resistance reverting activity and antitumor profile of new phenothiazine derivatives

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 13, 2008, Pages 6474-6482

  Bisi, Alessandra ^a   Meli, Maria ^b   Gobbi, Silvia ^a   Rampa, Angela ^a   Tolomeo, Manlio ^b   Dusonchet, Luisa ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Anticancer drugs; Apoptosis; Drug resistance; Phenothiazine derivatives

Indexed keywords

1 [4 (4 PHENOTHIAZIN 10 YLBUT 2 YNYL)PIPERAZIN 1 YL] 3 (4 TOLYLOXY)PROPAN 2 OL; 10 (4 MORPHOLIN 4 YLBUT 2 YNYL) 2 TRIFLUOROMETHYL 10H PHENOTHIAZINE; 10 (4 PIPERIDIN 1 YLBUT 2 YNYL) 10H PHENOTIAZINE; 10 [4 (4 METHYLPIPERAZIN 1 YL)BUT 2 YNYL] 10H PHENOTHIAZINE; 10 [4 (4 PHENYLPIPERAZIN 1 YL)BUT 2 YNYL] 10H PHENOTIAZINE; 10 [4 (4 PHENYLPIPERAZIN 1 YL)BUT 2 YNYL] 2 (TRIFLUOROMETHYL) 10H PHENOTHIAZINE; 10 [4 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)BUT 2 YNYL] 10H PHENOTHIAZINE; 10 [4 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]BUT 2 YNYL] 10H PHENOTHIAZINE; 2 CHLORO 10 (4 MORPHOLIN 4 YLBUT 2 YNYL) 10H PHENOTHIAZINE; 2 CHLORO 10 [4 (4 PHENYLPIPERAZIN 1 YL)BUT 2 YNYL] 10H PHENOTHIAZINE; 4 (4 PHENOTHIAZIN 10 YLBUT 2 YNYL)PIPERAZINE 1 CARBOXYLIC ACID ETHYL ESTER; [2 (3,4 DIMETHOXYPHENYL)ETHYL]METHYL (4 PHENOTHIAZIN 10 YL BUT 2 YNYL)AMINE; [2 (3,4 DIMETHOXYPHENYL)ETHYL]METHYL [4 (2 TRIFLUOROMETHYLPHENOTHIAZIN 10 YL)BUT 2 YNYL]AMINE; [4 (2 CHLOROPHENOTHIAZIN 10 YL)BUT 2 YNYL][2 (3,4 DIMETHOXYPHENYL)ETHYL]METHYLAMINE; CASPASE; CHLORPROMAZINE; DOXORUBICIN; GLYCOPROTEIN P; PHENOTHIAZINE DERIVATIVE; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG SYNTHESIS; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR STRUCTURE; PHENOTHIAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 44849117020     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.05.040     Document Type: Article

References (33)

1. Gottesmann M.M., Hrycyna C.A., Schoenlein P.V., Germann U.A., and Pastan I. Annu. Rev. Genet. 29 (1995) 607
2. Cole S.P.C., and Deeley R.G. Bioassays 20 (1998) 931
3. Grant C.E., Valdimarsson G., Hipfner D.R., Almquist K.C., Cole S.P., and Deeley R.G. Cancer Res. 54 (1994) 357
4. Kruh G.D., Chan A., Myers K., Gaughan K., Miki T., and Aaronson S.A. Cancer Res. 54 (1994) 1649
5. Kuwano M., Toh S., Uchiumi T., Takano H., Kohno K., and Wada M. Anti-Cancer Drug Des. 14 (1999) 123
6. Tsuruo T., Iida H., Tsukagoshi S., and Sakurai Y. Cancer Res. 41 (1981) 1967
7. Ford J.M., and Hait W.N. Pharmacol. Rev. 42 (1990) 155
8. Teodori E., Dei S., Scapecchi S., and Gualtieri F. Il Farmaco 57 (2002) 385
9. Crosta L., Candiloro V., Meli M., Tolomeo M., Rausa L., and Dusonchet L. Anticancer Res. 14 (1994) 2685
10. Reddy D.S. Drugs Future 22 6 (1997) 653
11. Seeling A., and Gatlik-Landwojtowicz P. Mini-Rev. Med. Chem. 5 (2005) 135
12. Klopman G., Srivastava S., Kolossvary I., Epand R.F., Ahmed N., and Epand R.M. Cancer Res. 52 (1992) 4121
13. Klopman G., Shi L.M., and Ramu A. Mol. Pharm. 52 (1997) 323
14. Krishna R., and Mayer L.D. Eur. J. Pharm. Sci. 11 (2000) 265
15. Notarbartolo M., Cervello M., Dusonchet L., Cusimano A., and D'Alessandro N. Cancer Lett. 180 (2002) 91
16. Shah M.A., and Schwartz G.K. Clin. Cancer Res. 7 (2001) 2168
17. Schwartz G.K., and Shah M.A. J. Clin. Oncol. 23 (2005) 9408
18. Tolomeo M., and Simoni D. Curr. Med. Chem.-Anti-Cancer Agents 2 (2002) 387
19. Mosnaim A.D., Ranade V.V., Wolf M.E., Puente J., and Antonieta Valenzuela M. Am. J. Ther. 13 (2006) 261
20. Motohashi N., Kawase M., Satoh K., and Sakagami H. Curr. Drug Targets 7 (2006) 1055
21. Molnar J., Hever A., Fakla I., Ocsovski I., and Aszalos A. Anticancer Res. 22 (2002) 2863
22. Michalak K., Wesolowska O., Motohashi N., Molnar J., and Hendrich A.B. Curr. Drug Targets 7 (2006) 1095
23. Ford M.J., Prozialeck W.C., and Hait W.N. Mol. Pharm. 35 (1989) 105
24. Tsakovska I.M. Bioorg. Med. Chem. 11 (2003) 2889
25. Voigt W., Romanelli M.N., Lemoine H., Mannhold R., Dei S., Teodori E., and Gualtieri F. Eur. J. Pharm., Mol. Pharmacol. Sec. 291 (1995) 255
26. Bisi A., Gobbi S., Rampa A., Belluti F., Piazzi L., Valenti P., Gyemant N., and Molnár J. J. Med. Chem. 49 (2006) 3049
27. Schuurhuis G.J., Pinedo H.M., Broxterman H.J., van Kalken C.K., Kuiper C.M., and Lankelma J. Int. J. Cancer 46 (1990) 330
28. Kabanov A.V., Batrakova E.V., and Alakhov V.Y. J. Control Release 91 (2003) 75
29. Dumont J.L., Chodkiewicz W., and Cadiot P. Bull. Soc. Chim. Fr. (1967) 1197
30. Dickinson, W. B. U.S. Patent 4065471, 1977.
31. In: Webb J.L. (Ed). Enzymes and Metabolic Inhibitors (1966), Academic Press, New York 66
32. Duke R.C., and Cohen J.J. In: Coligan J.E., and Kruisbeak A.M. (Eds). Current Protocols in Immunology (1992), John Wiley & Sons, New York 3.17.1
33. Darziynkiewick Z., Bruno S., Del Bino G., Gorczyca W., Holz M.A., Lassota P., and Traganos F. Cytometry 13 (1992) 795